![]() The targeted $20 million would help it prepare for those Phase 3 trials, slated to take place in the United States and Australia. Its technology was spun out of Melbourne’s Murdoch Children’s Research Institute in 2016, has cleared early testing hurdles around peanut allergy and needs to run large Phase 3 trials with 500 or more patients to shore it all up. Prota’s pitch is about developing and commercialising its treatment to combat food allergies. Prota Therapeutics’ technology was spun out of Murdoch Children’s Research Institute in 2016, and has been testing on kids with peanut allergies. Hot on the heels of a positive Phase 2b clinical trial result, Prota has hired global life sciences advisory firm Torreya and is scouring its network for strategic partners and financial investors to tip into the raising. Australian biotech Prota Therapeutics is chasing $20 million to prepare Phase 3 testing for what would be a world first peanut allergy treatment.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |